KDR and neoplasm: In this model, combination treatments (i.e., cotargeting VEGFR and PDGFR) demonstrated improved antitumor activity of progressive tumors, illuminating that optimal targeting approaches may need to consider prevention and intervention strategies as a component of the heterogeneity of the tumor-associated vasculature.